etravirine has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abdelrahman, M; Almadani, SA; ALsiyud, DF; Alzain, AA; Ashour, A; Ghazawi, KF; Ibraheem, W; Ibrahim, SRM; Miski, SF; Mohamed, GA; Osman, W; Sherif, AE; Shoaib, TH | 1 |
1 other study(ies) available for etravirine and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Exploring the potential of approved drugs for triple-negative breast cancer treatment by targeting casein kinase 2: Insights from computational studies.
Topics: Antineoplastic Agents; Casein Kinase II; Drug Approval; Female; Humans; Molecular Docking Simulation; Treatment Outcome; Triple Negative Breast Neoplasms | 2023 |